Glecaprevir/Pibrentasvir

格卡瑞韦/哌仑他韦

Report date: 2026/04/25 20:00:23

Base Information

Drug NameGlecaprevir/Pibrentasvir
Drug Alias Nameglecaprevir + pibrentasvirMavyret艾诺全MaviretABT-493/ABT-530
ClassificationSmall molecules
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4ANonstructural protein 5A
Therapy Area/IndicationsFibrosisHypersensitivityKidney Failure, Chronic +[6] 
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaHepatitis C, Chronic
Original Approved Country/TerritoryEU
Original Approved Date2017/07/26
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsYes PibrentasvirGlecaprevir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesFournier Laboratories Ireland LtdAbbvie CorpAbbvie Inc +[6] 
Inactive CompaniesKirby InstituteUniversity Of California San DiegoNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsKidney Failure, ChronicHepatitis C, ChronicHepatitis C
Inactive IndicationsFibrosisHypersensitivityHIV Infections

Other Information

ATC CodeJ05AP57
Related LinksKEGG